Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-1
SponsorNational Liver Institute, Egypt
About this trial
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Eligibility criteria
Qualifiers
Infants with initial diagnosis of biliary atresia with biliary atresia score > 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis.
Disqualifiers
Major cardiac, renal, pulmonary, neurological malformations or illnesses.
Hemoglobinopathies, such as sickle cell anemia
Active systemic infection.
White blood cell count > 20,000 cells/mm3.
Trial design
Treatments tested in this trial
- Granulocyte Colony-Stimulating Factor
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov